Claims for Patent: 11,939,361

Summary for Patent: 11,939,361

Title:	Compositions of peptide inhibitors of Interleukin-23 receptor
Abstract:	The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
Inventor(s):	Giustino Di Pretoro, Dajun SUN, Gopal Rajan, Geraldine BROECKX, Nathalie MERTENS, Shu Li, Felix Lai, Mohammad MASJEDIZADEH, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
Assignee:	Janssen Pharmaceutica NV , Protagonist Therapeutics Inc
Application Number:	US17/531,538
Patent Claims:	1. A pharmaceutical composition comprising: a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 15% (w/w) of the pharmaceutical composition; and one or more pharmaceutically acceptable excipients. 2. The pharmaceutical composition of claim 1, wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof, has the chemical structure: and wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is a pharmaceutically acceptable salt form. 3. The pharmaceutical composition of claim 1, wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is an acetate form. 4. The pharmaceutical composition of claim 3, wherein the acetate form is in an amorphous form. 5. The pharmaceutical composition of claim 1, wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 1 mg to about 1000 mg. 6. The pharmaceutical composition of claim 1, wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 10 mg to about 300 mg. 7. The pharmaceutical composition of claim 1, wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 25 mg to about 150 mg. 8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises an absorption enhancer. 9. The pharmaceutical composition of claim 8 comprising: a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 15% (w/w) of the pharmaceutical composition; an absorption enhancer in an amount from about 10% to about 60% (w/w); and one or more pharmaceutically acceptable excipients. 10. A method of treating an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 1. 11. A pharmaceutical composition comprising: a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 20% (w/w) of the pharmaceutical composition; and one or more pharmaceutically acceptable excipients. 12. The pharmaceutical composition of claim 11, wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof, has the chemical structure: and wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is a pharmaceutically acceptable salt form. 13. The pharmaceutical composition of claim 12, wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 1 mg to about 1000 mg. 14. The pharmaceutical composition of claim 13, wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 10 mg to about 500 mg. 15. The pharmaceutical composition of claim 14, wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 10 mg to about 300 mg. 16. A method of treating an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 11.